Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer

Next Previous
Trial Profile

A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Rucaparib (Primary) ; Prednisone
  • Indications Adenocarcinoma; Carcinoma; Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms RAMP
  • Sponsors Clovis Oncology [CEASED]; pharmaand GmbH

Most Recent Events

  • 26 Jun 2023 Status changed from active, no longer recruiting to completed.
  • 24 Jan 2022 Planned End Date changed from 1 May 2022 to 1 Oct 2022.
  • 21 May 2021 Results (as of 1 Oct 2020; n=8) assessing association between treatment response and gene alterations of known clinical significance in metastatic castration-resistant prostate cancer patients, presented at the 112th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top